Page 89 - 《中国药房》2024年8期

study：a Canadian analysis[J]. CMAJ Open，2018，6（2）： modifying agents for secondary cardiovascular disease
E162-E167. prevention among statin-treated patients in Thailand[J].
[18] OLRY DE LABRY LIMA A，GIMENO BALLESTER V， Pharmacoeconomics，2019，37（10）：1277-1286.
SIERRA SÁNCHEZ J F，et al. Cost-effectiveness and bu- [29] DRESSEL A，SCHMIDT B，SCHMIDT N，et al. Cost ef‐
dget impact of treatment with evolocumab versus statins fectiveness of lifelong therapy with PCSK9 inhibitors for
and ezetimibe for hypercholesterolemia in Spain[J]. Rev lowering cardiovascular events in patients with stable
Esp Cardiol，2018，71（12）：1027-1035. coronary artery disease：insights from the Ludwigshafen
[19] ARRIETA A，PAGE T F，VELEDAR E，et al. Economic risk and cardiovascular health cohort[J]. Vascul Pharma‐
evaluation of PCSK9 inhibitors in reducing cardiovascular col，2019，120：106566.
risk from health system and private payer perspectives[J]. [30] KORMAN M， WISLØFF T. Modelling the cost-
PLoS One，2017，12（1）：e0169761. effectiveness of PCSK9 inhibitors vs. ezetimibe through
[20] BORISSOV B，URBICH M，GEORGIEVA B，et al. Cost- LDL-C reductions in a Norwegian setting[J]. Eur Heart J
effectiveness of evolocumab in treatment of heterozygous Cardiovasc Pharmacother，2018，4（1）：15-22.
familial hypercholesterolaemia in Bulgaria：measuring [31] STAM-SLOB M C，VAN DER GRAAF Y，DE BOER A，
health benefit by effectively treated patient-years[J]. J et al. Cost-effectiveness of PCSK9 inhibition in addition
Mark Access Health Policy，2017，5（1）：1412753. to standard lipid-lowering therapy in patients at high risk
[21] FONAROW G C，KEECH A C，PEDERSEN T R，et al. for vascular disease[J]. Int J Cardiol，2018，253：148-154.
Cost-effectiveness of evolocumab therapy for reducing [32] KAZI D S，MORAN A E，COXSON P G，et al. Cost-
effectiveness of PCSK9 inhibitor therapy in patients with
cardiovascular events in patients with atherosclerotic car‐
heterozygous familial hypercholesterolemia or atheroscle‐
diovascular disease[J]. JAMA Cardiol，2017，2（10）：1069-
rotic cardiovascular disease[J]. JAMA，2016，316（7）：
1078.
743-753.
[22] KAZI D S，PENKO J，COXSON P G，et al. Updated cost-
[33] MORAN A E，ODDEN M C，THANATAVEERAT A，et
effectiveness analysis of PCSK9 inhibitors based on the
al. Cost-effectiveness of hypertension therapy according
results of the FOURIER trial[J]. JAMA，2017，318（8）：
to 2014 guidelines[J]. N Engl J Med，2015，372（5）：
748-750.
447-455.
[23] TOTH P P，DANESE M，VILLA G，et al. Estimated bur‐
[34] GRUNDY S M，STONE N J，BAILEY A L，et al. 2018
den of cardiovascular disease and value-based price range
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/
for evolocumab in a high-risk，secondary-prevention popu‐
ASPC/NLA/PCNA guideline on the management of blood
lation in the US payer context[J]. J Med Econ，2017，20
cholesterol：executive summary：a report of the American
（6）：555-564.
College of Cardiology/American Heart Association Task
[24] VILLA G，LOTHGREN M，KUTIKOVA L，et al. Cost-
Force on clinical practice guidelines[J]. Circulation，2019，
effectiveness of evolocumab in patients with high cardio-
139（25）：e1046-e1081.
vascular risk in Spain[J]. Clin Ther，2017，39（4）：771-
[35] MACH F，BAIGENT C，CATAPANO A L，et al. 2019
786.e3.
ESC/EAS guidelines for the management of dyslipidae‐
[25] GANDRA S R，VILLA G，FONAROW G C，et al. Cost-
mias：lipid modification to reduce cardiovascular risk[J].
effectiveness of LDL-C lowering with evolocumab in pa‐
Eur Heart J，2020，41（1）：111-188.
tients with high cardiovascular risk in the United States[J].
[36] Atherosclerosis and Coronary Heart Disease Working
Clin Cardiol，2016，39（6）：313-320.
Group of Chinese Society of Cardiology，Editorial Board
[26] MICHAELI D T，MICHAELI J C，BOCH T，et al. Cost- of Chinese Journal of Cardiology. Chinese expert consen‐
effectiveness of lipid-lowering therapies for cardiovascu‐ sus on lipid management of very high-risk atherosclerotic
lar prevention in Germany[J]. Cardiovasc Drugs Ther， cardiovascular disease patients[J]. Zhonghua Xin Xue
2023，37（4）：683-694. Guan Bing Za Zhi，2020，48（4）：280-286.
[27] MICHAELI D T，MICHAELI J C，BOCH T，et al. Cost- [37] 王增武，刘静，李建军，等 . 中国血脂管理指南：2023 年
effectiveness of icosapent ethyl，evolocumab，alirocumab， [J]. 中国循环杂志，2023，38（3）：237-271.
ezetimibe，or fenofibrate in combination with statins com‐ WANG Z W，LIU J，LI J J，et al. Chinese guidelines for
pared to statin monotherapy[J]. Clin Drug Investig，2022， lipid management：2023[J]. Chin Circ J，2023，38（3）：
42（8）：643-656. 237-271.
[28] KONGPAKWATTANA K，ADEMI Z，CHAIYASOTHI T， （收稿日期：2023-10-16 修回日期：2024-03-11）
et al. Cost-effectiveness analysis of non-statin lipid- （编辑：孙 冰）

中国药房 2024年第35卷第8期 China Pharmacy 2024 Vol. 35 No. 8 · 979 ·